The case for non-penetrating glaucoma surgery


Personal experience in a wider context

To date, raised intraocular pressure (IOP) remains the only modifiable risk factor in glaucoma management. The aim of glaucoma surgery is to lower IOP and thus curb the progression of glaucomatous optic nerve damage, especially in cases refractory to topical therapy.

While full-thickness trabeculectomy penetrates the eye, NPGS does not. With the globe remaining intact, there is a relatively controlled flow of aqueous through the TDM, thus preventing sudden intra- and postoperative hypotony. The superior safety profile of NPGS as compared with full-thickness trabeculectomy is further evidenced by a relatively low risk of blebitis and endophthalmitis.1

Even though there is an extensive literature devoted to fullthickness glaucoma surgery, sufficiently large and comparable longterm studies reporting on the efficacy and reproducibility of NPGS are pending. This is one of the main reasons why, despite its apparent advantages, NPGS is not widely performed.

Variants of NPGS

The idea of NPGS was first explored in the 1960s. Today, the basic NPGS procedure can be described as a deep sclerectomy (DS). In addition, NPGS encompasses viscocanalostomy and canalopasty, both of which aim to increase flow through Schlemm's canal.3

DS can be combined with spacemaintainer implants, the aim of which is to avoid secondary collapse of the superficial flap. The use of antimetabolites such as mitomycin C (MMC) reduces the risk of bleb scarring and, therefore, enhances the rate of success of NPGS, which, although to a lesser extent than trabeculectomy, is bleb dependent.

Operative technique

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.